Annals of Oncology · 2014 · 30 citations · 0 references
PharmacyOncologyPharmacotherapyCancer ImmunologyImmunotherapyTumor ImmunologyAntibody CharacterizationCancer ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy SafetyMonoclonal Antibodies In OncologyPd-l1 BlockadeProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-1 InhibitionProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 Targeting